FSD Pharma: Rises on seeking nod to begin mid-stage trial of COVID-19 treatment

Quantum Biopharma

31/08/2020 11:32

** U.S.-listed shares of Canadian pharma co  HUGE.O  rise
17.3% to $3.8 in premarket trade - set for their best day in
almost three months 
    ** Co says its has filed an application to the U.S. FDA to
begin mid-stage trial of its experimental drug to treat
hospitalized COVID-19 patients  urn:newsml:reuters.com:*:nBw7jkqt0a
    ** The study is expected to be conducted at 25-30 hospitals
in North America - HUGE
    ** The study will test the efficacy and safety of co's drug
at 600 mg or 1200 mg twice-daily, along with standard of care,
compared with standard of care alone in hospitalized patients
with COVID-19
    ** Up to Friday's close, stock is down 40% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))